VTX002 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎5

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003050-23-LT
(EUCTR)
25/01/202211/10/2021VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis Moderately to Severely Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Oppilan Pharma Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2Belarus;United States;Czechia;Ukraine;Lithuania;Israel;Russian Federation;Italy;Hungary;Czech Republic;Poland;Georgia;Germany
2EUCTR2021-003050-23-PL
(EUCTR)
02/01/202229/09/2021VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis Moderately to Severely Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002
Oppilan Pharma Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2United States;Belarus;Czechia;Ukraine;Lithuania;Israel;Russian Federation;Italy;Hungary;Czech Republic;Poland;Georgia;Germany
3NCT05156125
(ClinicalTrials.gov)
November 30, 20211/12/2021VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeDrug: VTX002;Drug: PlaceboOppilan Pharma LtdNULLRecruiting18 Years80 YearsAll180Phase 2United States;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Lithuania;Poland;Serbia;Slovakia;Ukraine
4EUCTR2021-003050-23-HU
(EUCTR)
22/11/202101/10/2021VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis Moderately to Severely Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Oppilan Pharma Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2Belarus;United States;Czechia;Ukraine;Lithuania;Israel;Russian Federation;Italy;Hungary;Czech Republic;Poland;Georgia;Germany
5EUCTR2021-003050-23-CZ
(EUCTR)
25/10/202118/08/2021VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisA Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis Moderately to Severely Active Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Product Code: VTX002
INN or Proposed INN: not yet available
Other descriptive name: VTX002 is not biologic
Oppilan Pharma Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 2Belarus;United States;Czechia;Ukraine;Lithuania;Israel;Russian Federation;Italy;Czech Republic;Hungary;Poland;Georgia;Germany